RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC + RZ358 (10 mg/kg) or Placebo + SOC + RZ358 (5-10 mg/kg) + SOC

About RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC + RZ358 (10 mg/kg) or Placebo + SOC + RZ358 (5-10 mg/kg) + SOC

RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC + RZ358 (10 mg/kg) or Placebo + SOC + RZ358 (5-10 mg/kg) + SOC is a phase 3 stage product being developed by Rezolute for Congenital Hyperinsulinism. The current trial status is active. This product is registered under clinical trial identifier NCT06208215. Target conditions include Congenital Hyperinsulinism.

What happened to similar drugs?

4 of 20 similar drugs in Congenital Hyperinsulinism were approved

Hype Score Breakdown